114 patents currently held
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
38 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Jan 2027
Next term end
53
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2031 · High confidence
Also notable
Ends Jan 2033 · High confidence
Also notable
Ends Feb 2036 · High confidence
Controlled Release Dosage Forms for High Dose, Water Soluble and Hygroscopic Drug Substances
US 10,987,310
Cited by 105 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Gamma-Hydroxybutyrate Compositions and Their Uses for the Treatment of Disorders
US 11,554,102
Cited by 36 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
GHB Formulation and Method for Its Manufacture
US 11,364,215
Cited by 36 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036.
Formerly held, still cited
Notable
Ends Jun 2038 · High confidence
Cited by 71 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
now held by Axsome Malta Ltd.
Also notable
Ends Mar 2040 · High confidence
Cited by 50 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2040.
now held by Axsome Malta Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for Novel Reference Plant, a Method for Its Production, Extracts Obtained Therefrom and Their Use (US 9,035,130) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
- 2 fees due Dec 9 to 30, 2026 · next Dec 9
- 1 fee due Feb 6, 2027The maintenance fee for Imipridones for Gliomas (US 10,369,154) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 3 fees due Mar 5 to 15, 2027 · next Mar 5
- 4 fees due Apr 17 to 30, 2027 · next Apr 17
- 1 fee due May 28, 2027The maintenance fee for Pegylated L-Asparaginase (US RE49,736) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Remote Loading of Sparingly Water-Soluble Drugs into Liposomes (US 10,507,182) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Fused Bicyclic Raf Inhibitors and Methods for Use Thereof (US 11,858,930) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Aug 23 to 25, 2027 · next Aug 23
- 1 fee due Sep 1, 2027The maintenance fee for Compositions for Delivery of Drug Combinations (US 9,271,931) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
What they patent
The 5 largest of its 53 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Gamma-Hydroxybutyrate Compositions and Their Use for the Treatment of Disorders | 16 in force | to Sep 2037 |
| Controlled Release Dosage Forms for High Dose, Water Soluble and Hygroscopic Drug Substances | 7 in force | to Mar 2031 |
| Imipridones for Gliomas | 6 in force | to Jan 2037 |
| 7-Benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | 5 in force | to Jul 2034 |
| Modified L-Asparaginase | 3 in force | to Aug 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,850,990 | Compositions for Delivery of Drug Combinations In force · Medium confidence | In force | Medium confidence | |
| US 7,700,368 | Methods of Purifying Cannabinoids from Plant Material In force · High confidence | In force | High confidence | |
| US 8,481,085 | Pharmaceutical Compositions Comprising Cannabigerol In force · High confidence | In force | High confidence | |
| US 8,022,279 | Liposomal Formulations of Anthracycline Agents and Cytidine Analogs In force · Medium confidence | In force | Medium confidence | |
| US 9,168,278 | Use for Cannabinoid In force · High confidence | In force | High confidence | |
| US 9,795,567 | Immediate Release Formulations and Dosage Forms of Gamma-Hydroxybutyrate In force · Medium confidence | In force | Medium confidence | |
| US 9,017,737 | Use of Cannabinoids in Combination with an Anti-Psychotic Medicament In force · High confidence | In force | High confidence | |
| US 7,842,676 | Fixed Ratio Drug Combination Treatments for Solid Tumors In force · High confidence | In force | High confidence | |
| US 8,092,828 | Fixed Drug Ratios for Treatment of Hematopoietic Cancers and Proliferative Disorders In force · High confidence | In force | High confidence | |
| US 8,778,398 | Immediate Release Formulations and Dosage Forms of Gamma-Hydroxybutyrate In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 114: 17 patents in force now held by others · 29 patents ended · 46 applications pending · 47 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.